Abstract
Primary signet-ring cell carcinoma (SRCC) of the urinary bladder, a variant of adenocarcinoma, is exceedingly rare and as a result no gold standard exists for its management. We report a case of primary SRCC of the bladder with recurrent metastases; we utilized an innovative diagnostic approach and the patient exhibited a treatment response to palliative FOLFOX-6 chemotherapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | E204-E207 |
| Journal | Journal of the Canadian Urological Association |
| Volume | 9 |
| Issue number | 3-4APRIL |
| DOIs | |
| State | Published - Apr 13 2015 |
Fingerprint
Keywords
- Bladder cancer
- FOLFOX-6
- Metastatic
- Next generation sequencing
- Signet-ring cell carcinoma
ASJC Scopus subject areas
- Oncology
- Urology
Cite this
Metastatic signet-ring cell carcinoma of the urinary bladder : A novel management approach to a rare tumour. / Pugashetti, Neil; Stanley, A.; Primo, N.; Regina, Gandour Edwards; Marc, A.
In: Journal of the Canadian Urological Association, Vol. 9, No. 3-4APRIL, 13.04.2015, p. E204-E207.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metastatic signet-ring cell carcinoma of the urinary bladder
T2 - A novel management approach to a rare tumour
AU - Pugashetti, Neil
AU - Stanley, A.
AU - Primo, N.
AU - Regina, Gandour Edwards
AU - Marc, A.
PY - 2015/4/13
Y1 - 2015/4/13
N2 - Primary signet-ring cell carcinoma (SRCC) of the urinary bladder, a variant of adenocarcinoma, is exceedingly rare and as a result no gold standard exists for its management. We report a case of primary SRCC of the bladder with recurrent metastases; we utilized an innovative diagnostic approach and the patient exhibited a treatment response to palliative FOLFOX-6 chemotherapy.
AB - Primary signet-ring cell carcinoma (SRCC) of the urinary bladder, a variant of adenocarcinoma, is exceedingly rare and as a result no gold standard exists for its management. We report a case of primary SRCC of the bladder with recurrent metastases; we utilized an innovative diagnostic approach and the patient exhibited a treatment response to palliative FOLFOX-6 chemotherapy.
KW - Bladder cancer
KW - FOLFOX-6
KW - Metastatic
KW - Next generation sequencing
KW - Signet-ring cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84928014346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928014346&partnerID=8YFLogxK
U2 - 10.5489/cuaj.2447
DO - 10.5489/cuaj.2447
M3 - Article
AN - SCOPUS:84928014346
VL - 9
SP - E204-E207
JO - Journal of the Canadian Urological Association
JF - Journal of the Canadian Urological Association
SN - 1911-6470
IS - 3-4APRIL
ER -